Last update 20 Mar 2025

Neostigmine Methylsulfate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(m-Hydroxyphenyl)trimethylammonium dimethylcarbamate, 3-Trimethylammoniumphenyl N,N-dimethylcarbamate, Eustigmin
+ [12]
Target
Action
inhibitors, antagonists
Mechanism
AChE inhibitors(Acetylcholinesterase inhibitors), Muscle relaxation antagonists
Inactive Indication-
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
Japan (01 Oct 1936),
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC13H22N2O6S
InChIKeyOSZNNLWOYWAHSS-UHFFFAOYSA-M
CAS Registry51-60-5
View All Structures (2)

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Reversal of Neuromuscular Blockade
Japan
13 Mar 2001
Flatulence
China
01 Jan 1995
Urinary Retention
China
01 Jan 1995
Dyspnea
Japan
01 Oct 1936
Dysuria
Japan
01 Oct 1936
Myasthenia Gravis
Japan
01 Oct 1936
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
235
(Neostigmine)
zhzqnwfaea(wtjwoetqtx) = vxcjyszqht xqmrhtrpwj (mseocxtqwv, nliwdkkusj - zefggrdulp)
-
09 Oct 2024
(Sugammadex)
zhzqnwfaea(wtjwoetqtx) = axqhhzhgyt xqmrhtrpwj (mseocxtqwv, nkxpklviey - mjljyesqro)
Not Applicable
-
maubanwvud(ppjihpduoe): RR = 0.37 (95% CI, 0.26 - 0.54)
-
18 May 2024
(Decompressive Colonoscopy)
Not Applicable
-
yzstuyaibx(fiscqfrlll): RR = 0.37 (95% CI, 0.26 - 0.54)
-
18 May 2024
(Decompressive colonoscopy)
Not Applicable
-
lwopczfqah(vgufrlqkkd): RR = 0.37 (95% CI, 0.26 - 0.54)
-
18 May 2024
(Decompressive Colonoscopy)
Not Applicable
-
ujsjixwidx(bgqvhyomyc): RR = 0.37 (95% CI, 0.26 - 0.54)
-
18 May 2024
(Decompressive Colonoscopy)
Phase 4
84
(Neostigmine/Glycopyrrolate)
(oiiqanuvns) = yyvgxulvaw hciwexxwsb (cuwwebaxze, zmxupyawdl - todovshpuo)
-
22 Dec 2023
(oiiqanuvns) = hjjcsmslaw hciwexxwsb (cuwwebaxze, esjetnfhph - yiqzicqefw)
Phase 2
49
(Cisatracurium + Neostigmine)
nxeywjccyx(rjunrzmruq) = fbqblkjptf hdtsvkzahy (ejxsuxmtso, vxmraynksj - fxiesgnybc)
-
03 Jul 2023
(Rocuronium + Sugammadex)
nxeywjccyx(rjunrzmruq) = yifelxwjam hdtsvkzahy (ejxsuxmtso, paaqbjziro - xahcozddre)
Phase 2
167
standard therapy+Neostigmine
kmqyixsalk(ikonqxgpsl) = cggidgxxft ndcowrffbq (bulmjohjtk )
Positive
07 Mar 2022
standard therapy+0.9% saline
kmqyixsalk(ikonqxgpsl) = pysksswiqu ndcowrffbq (bulmjohjtk )
Phase 2
80
iwnjodovdj(xfrllycudw) = okihatiwzz dvjboewkyw (ipyfyzteft, [-28.4 - -4.7])
Positive
03 Mar 2022
Not Applicable
-
40
isjyklcvky(wkuhgoyppa) = phqkpqbgon uriicidtuq (pvvduyypsv )
-
01 Dec 2021
isjyklcvky(wkuhgoyppa) = lzxjaqfkpx uriicidtuq (pvvduyypsv )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free